Cystic Fibrosis (CF) Therapeutics Global Market Research Report 2024: Burgeoning Emphasis on Personalized Medicine and Targeted Therapies - Long-term Forecasts to 2028 and 2033 [Yahoo! Fin...
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
The cystic fibrosis (cf) therapeutics market size has grown rapidly in recent years. It will grow from $6.91 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The cystic fibrosis (cf) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The growth observed in the historic period can be attributed to several factors, including advancements in targeted therapies, a deeper understanding of cystic fibrosis (CF) genetics, increased patient advocacy and awareness, government support for research initiatives, and incentives for rare disease research, such as orphan drug designations. These elements collective
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses [Yahoo! Finance]Yahoo! Finance
- New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment PausesBusiness Wire
- Public advisory - One lot of ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion recalled due to an impurity that may pose health risks [Yahoo! Finance]Yahoo! Finance
- Napoli Shkolnik Applauds U.S. Supreme Court Decision to Reject Liability Shield at Center of Purdue Pharma Settlement; Will Pursue Litigation Against Sacklers [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Jefferies Financial Group Inc. from $19.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
TEVA
Earnings
- 5/8/24 - Miss
TEVA
Sec Filings
- 6/25/24 - Form 8-K
- 6/21/24 - Form 4
- 6/18/24 - Form 144
- TEVA's page on the SEC website